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Background Diabetes mellitus, particularly type 2 diabetes, is a major public health bur-
den globally. Diabetes is known to be associated with several comorbidities in high-income 
countries. However, our understanding of these associations in low- and middle-income 
countries (LMICs), where the epidemiological transition is leading to a growing dual bur-
den of non-communicable and communicable disease, is less clear. We therefore conduct-
ed an umbrella review to systematically identify, appraise and synthesise reviews reporting 
the association between diabetes and multiple key comorbidities in LMICs.
Methods We searched Medline, Embase, Global Health, and Global Index Medicus from 
inception to 14 November 2020 for systematic reviews, with or without meta-analyses, of 
cohort, case-control or cross-sectional studies investigating the associations between dia-
betes and cardiovascular disease (CVD), chronic kidney disease (CKD), depression, den-
gue, pneumonia, and tuberculosis within LMICs. We sought reviews of studies focused on 
LMICs, but also included reviews with a mixture of high-income and at least two LMIC 
studies, extracting data from LMIC studies only. We conducted quality assessment of iden-
tified reviews using an adapted AMSTAR 2 checklist. Where appropriate, we re-ran me-
ta-analyses to pool LMIC study estimates and conduct subgroup analyses.
Results From 11 001 articles, we identified 14 systematic reviews on the association be-
tween diabetes and CVD, CKD, depression, or tuberculosis. We did not identify any eli-
gible systematic reviews on diabetes and pneumonia or dengue. We included 269 studies 
from 29 LMICs representing over 3 943 083 participants. Diabetes was positively associ-
ated with all comorbidities, with tuberculosis having the most robust evidence (16 of 26 
cohort studies identified in total) and depression being the most studied (186 of 269 stud-
ies). The majority (81%) of studies included were cross-sectional. Heterogeneity was sub-
stantial for almost all secondary meta-analyses conducted, and there were too few studies 
for many subgroup analyses.
Conclusions Diabetes has been shown to be associated with several comorbidities in LMICs, 
but the nature of the associations is uncertain because of the large proportion of cross-sec-
tional study designs. This demonstrates the need to conduct further primary research in 
LMICs, to improve, and address current gaps in, our understanding of diabetes comorbid-
ities and complications in LMICs.
Cite as: Lam AA, Lepe A, Wild SH, Jackson C. Diabetes comorbidities in low- and 
middle-income countries: An umbrella review. J Glob Health 2021;11:04040.
Diabetes affected an estimated 463 million people in 2019, a number that is expected to grow 
to approximately 700 million by 2045 [1]. Of people with diabetes, about 90% have type 2 
diabetes and almost 80% live in low- and middle-income countries (LMICs), where preva-
lence is increasing most rapidly [1]. This increasing prevalence reflects the epidemiological 
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[2]. As more people develop diabetes in LMICs which already have a major burden of infectious diseases, 
health systems must adapt to provide the joint care necessary to treat and manage the comorbidities with 
which diabetes is associated. However, for this to be done it is important to understand which conditions 
related to diabetes are most relevant in LMICs and establish the strength of evidence for the association of 
diabetes with these conditions. Although the focus of this paper is on type 2 diabetes, we will use the gen-
eral term diabetes as many studies do not distinguish between type 1 or type 2 diabetes. This review uses 
the term comorbidities, rather than comorbidities and complications, of diabetes, but we acknowledge that 
certain conditions such as macrovascular disease or depression may exist as either a comorbidity or as a 
complication of diabetes.
Much of the evidence on diabetes comorbidities stems from high-income countries (HICs) [3-6]. However, 
these findings cannot necessarily be extrapolated to LMICs, where context-specific factors might influence as-
sociations. Moreover, various infectious diseases which may be related to diabetes are more common in LMICs. 
We identified six key conditions for which diabetes is thought to be a risk factor or for which there may be a 
bi-directional association, and which are particularly relevant to the LMIC setting. Non-communicable diseases 
including cardiovascular disease (CVD), chronic kidney disease (CKD), and depression are highly prevalent in 
HICs and associated with diabetes, but are also leading contributors to the burden of disease as measured by 
disability-adjusted life years (DALYs) in LMICs [7-11]. Three communicable diseases which have been linked 
to diabetes are dengue and tuberculosis (TB), which are most prevalent in LMICs, and pneumonia which is 
common globally [12,13].
Given the expanding literature on the association between diabetes and comorbidities, there is a need to syn-
thesise this information to give a comprehensive overview of this topic in the context of LMIC settings. We 
therefore conducted an umbrella review of systematic reviews and meta-analyses to provide an overview of 
the breadth and strength of the existing evidence on the association between diabetes and the aforementioned 
comorbidities in LMICs.
METHODS
This umbrella review was performed according to the guidelines laid out by Aromataris et al. [14].
Search strategy
We searched Medline, Embase, Global Health, and Global Index Medicus from inception up to 14 Novem-
ber 2020 to identify systematic reviews of observational studies on the association between diabetes and CVD, 
CKD, dengue, depression, pneumonia, and TB. CVD encompassed coronary heart disease, myocardial in-
farction, angina, stroke and transient ischaemic attack, since diabetes has been shown to be associated with a 
markedly higher risk of these conditions [15]. The search included variations of the following as MeSH terms 
or keywords: diabetes, CVD, CKD, dengue, depression, pneumonia, and TB, as well as terms for LMICs, in-
cluding individual country names (Appendix S1 in the Online Supplementary Document) [16]. We also 
perused reference lists of identified relevant studies. Two authors (AAL and AL) independently screened titles, 
abstracts, and full-text articles. Any discrepancies were resolved through discussion.
Inclusion and exclusion criteria
We included systematic reviews, with or without meta-analyses, if they included cross-sectional, case-control 
or cohort primary studies. Primary studies had to have evaluated the prevalence or incidence of the relevant 
comorbidity in people with diabetes or the role of diabetes as a risk factor for the subsequent development of 
the condition. We included reviews of primary studies conducted solely in LMICs, or from a mixture of HICs 
and LMICs if at least two studies within a review were from an LMIC. Only LMIC studies from the latter were 
used in the analysis.
We excluded reviews which: focused on the association between diabetes and its comorbidities in the context 
of a third disease (for example, those which solely examined the association between diabetes and TB in an 
HIV-positive population); included diabetes as the outcome or focused solely on type 1 diabetes mellitus or 
gestational diabetes; examined studies of mortality outcomes; or were not conducted systematically (ie, narra-
tive reviews, commentaries, editorials). Although our search strategy did not exclude non-English articles, we 
ultimately excluded articles written in languages other than English, Spanish, or Portuguese.
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Study selection
If multiple reviews included overlapping primary studies, the review which was most comprehensive (eg, 
greater number of LMIC studies) was included. If reviews on the same outcome focused on different settings 
(for example, one country vs multiple), both were included. If there were prevalence and incidence or associ-
ation reviews on the same comorbidity, provided they did not overlap in terms of primary studies or settings, 
all eligible studies were included.
Data extraction
Data were extracted independently by two authors (AAL and AL) using a standardised form adapted from the 
Joanna Briggs Institute [14]. Any discrepancies were resolved through discussion. If a review included pri-
mary studies from both HICs and LMICs, we only extracted data pertaining to LMIC studies. We categorised 
LMICs based on the World Bank’s historical income classification at the beginning of the primary study period 
[17]. Thus, the same country may be classified in different income levels depending on when the study began. 
We extracted the following data from reviews: first author; year; number of included LMIC primary studies; 
study designs; study settings; number of participants; country of primary study; population; exposure; expo-
sure ascertainment; comparators (if any); outcome; outcome ascertainment; databases searched; and quality 
assessment method. For eligible meta-analyses, we extracted the following additional data items: study peri-
od; meta-analysis metric; number of outcomes (if more than one); type of model; factors adjusted for; effect 
estimate with 95% confidence interval; variables that were adjusted for; measures of heterogeneity (Q and/or 
I2) with P values; and measures of publication bias (Egger’s Test and/or Begg’s Test). If necessary data were not 
provided, or if there were any discrepancies identified in the review, we examined primary studies to extract 
the appropriate information.
Quality appraisal
The methodological quality of both systematic reviews and meta-analyses was assessed independently by two 
authors (AAL and AL) using an adapted version of the AMSTAR 2 checklist (Appendix S2 in the Online Sup-
plementary Document) [18]. AMSTAR 2 is an improved version of AMSTAR, a tool designed for the critical 
appraisal of systematic reviews of non-randomised and/or randomised studies of health care interventions. 
AMSTAR 2 is more inclusive to systematic reviews of observational studies and is comprised of the following 
domains: methods (ie, proper reporting of PICO, protocol, search strategy, eligibility criteria, data extraction 
and analysis), quality assessment (ie, risk of bias appraisal), and meta-analysis methods (ie, appropriate meth-
ods, investigation of heterogeneity and publication bias). Where the AMSTAR 2 checklist asked about ran-
domised and non-randomised studies separately, we removed the parts related to randomised studies so the 
focus could be on observational studies. We also included an additional question on the type of quality ap-
praisal tool used and whether quality descriptions were provided.
The checklist uses a rating system of high, moderate, low, and critically low confidence in the results, which 
is based on how well the identified review covers the domains deemed to be most important to the validity of 
umbrella reviews [18]. The critical domains included: adequate search strategy, sufficient reporting of study 
characteristics, risk of bias/quality appraisal, appropriate meta-analytical methods, accounting for risk of bias 
during results interpretation, and assessment of publication bias. If one critical domain was missing, the re-
view was automatically dropped to a low confidence. If two or more critical domains were missing, the review 
was given a critically low confidence and thus excluded.
Statistical analysis
For systematic reviews which did not conduct a meta-analysis, or for which we did not conduct a secondary 
meta-analysis, we conducted narrative syntheses, which comprised a summary of primary study characteris-
tics and main findings. For reviews which did include a meta-analysis, all included meta-analyses were re-run 
using random-effect models and summary estimates were pooled based on the reported effect estimates from 
each review [19]. Where reviews included both HIC and LMIC studies in their meta-analysis, we only includ-
ed the LMIC studies in our secondary meta-analysis. We extracted the following information for each primary 
study from an LMIC to conduct the secondary meta-analysis: first author; year; country of study; study design; 
study size; income classification of country at first year of study period; study population; any information on 
diagnosis or type of exposure or outcome; effect estimate; and 95% confidence intervals (CIs).
We assessed heterogeneity using the I2 metric, with I2<50%, I2 = 50%-75% and I2>75% suggesting low, mod-
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a sufficient number of studies, pre-defined sub-
group analyses (study design and country income 
level) were conducted to explore potential sourc-
es of heterogeneity. If the identified meta-analy-
sis conducted relevant subgroup analyses, we also 
re-ran those analyses if included primary studies 
differed or if the original analysis was not pooled 
using random effects models. If a review includ-
ed at least ten primary studies, we explored pub-
lication bias using a funnel plot and Egger’s test to 
evaluate whether smaller studies contribute more 
to the effect estimate compared with larger stud-
ies [21]. For prevalence meta-analyses, we did not 
assess publication bias because these funnel plots 
were found to be inaccurate [22].
We used Stata version 16 (StataCorp LLC, Col-
lege Station, Texas, USA) to conduct secondary 
meta-analyses [23].
RESULTS
Our search identified 11 001 articles, of which 
23 were eligible for inclusion following full-text 
screening (Figure 1). Reviews which were exclud-
ed following full-text screening are listed in Table 
S1 in the Online Supplementary Document. Af-
ter quality assessment, we excluded nine reviews 
of critically low confidence mainly due to insuffi-
cient primary study details and lack of risk of bias 
or quality appraisal (Table S2 in the Online Sup-
plementary Document). We therefore included 
a total of 14 reviews, which focused on diabetes in relation to CVD (two reviews) [24,25], CKD (two reviews) 
[26,27], depression (five reviews) [28-32], and TB (five reviews) [33-37] (Table 1). We did not identify any 
eligible reviews on the association between diabetes and pneumonia. For dengue, one review met our inclu-
sion criteria [38], but was rated as being of critically low confidence and was thus excluded from our final se-
Figure 1. 
Figure 1. PRISMA flow diagram detailing the study selection process.
Table 1. Distribution of primary study designs and number of participants by comorbidity and country income level from included system-
atic reviews and meta-analyses


































































































Depression 0 3 183 186 528 987† 8 7 1 16 838 399 86.1 38.2
Chronic kidney disease 4 1 9 14 5 189 69 0 0 69 820 138 2.82 0.14
Cardiovascular disease‡ 6 6 10 22 3 108 248 20 1 21 42 1 440 950 34.4 68.3















180 61 386 417 59.9 6.42
LMIC – low- and middle-income country
* These primary studies are from the systematic reviews and meta-analyses which included studies from high-income countries and were included in this um-
brella review.
†This number does not include the participants from Uphoff et al. [29] since they did not provide individual study characteristics.
‡One primary study from Einarson et al. [24] included low, middle, and high-income countries and was thus not included in this table.
§ One primary study from McMurry et al. [34] included data on two separate cross-sectional studies, so both were included in the cross-sectional but not pri-
mary study count.
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lection (Table S2 in the Online Supplementary Document). Therefore, we included five reviews in the nar-
rative synthesis and nine in the secondary meta-analysis.
This umbrella review represented data from over 3 943 083 participants across 26 cohort, 25 case-control, and 
219 cross-sectional studies from 29 LMICs. This number of participants does not include those from the 41 
cross-sectional studies included in the included review by Uphoff et al. [29] which did not provide this infor-
mation. Of the 14 included reviews, only eight [25,27-31,33,34] focused solely on LMICs. The other six re-
views included a mix of primary studies from HICs and LMICs, with the majority often being from HICs. As 
shown in Table 2, there were relatively few cohort studies, and among the mixed income level reviews, there 
were far fewer cohort studies conducted in LMICs than in HICs. Among the diabetes comorbidities of inter-
est, cohort studies were used most often to investigate TB, with 16 cohort studies identified. Depression was 
the most studied comorbidity in terms of volume of primary studies, although almost all were cross-sectional 
(183 of 186 studies).
It is difficult to provide exact numbers of primary studies per country income level since assignment of stud-
ies to income level varied depending on the beginning of the study period. Nevertheless, the majority of LMIC 
primary studies were from a middle-income country. All WHO regions were represented, with eight coun-
tries from the African Region, six from the Eastern Mediterranean Region, four from each of the European, 
South-East Asia, and Western Pacific Regions, and three from the Region of the Americas. Iran and India had 
the most studies at 61 and 60, respectively, followed by China (19), Ethiopia (14), and Mexico (13). Eleven 
countries were only represented once, and the remaining countries had generally 5 or fewer studies. Except 
for CKD, each outcome had at least one study from each WHO region, with TB including the greatest num-
ber of countries (22). Seventy-eight percent of participants (3 060 517) came from a single Russian cross-sec-
tional study [39] and many studies were from Iran and India due to country-specific reviews including 44 and 
43 cross-sectional studies, respectively [30,31]. One review was assessed to be of high confidence [37], ten of 
moderate confidence [24,26,29-36] and three of low confidence [25,27,28] (Table 1 and more detailed ap-
praisal in Table S2 in the Online Supplementary Document). Main findings for each systematic review and 
meta-analysis are summarised in Table 3.
Cardiovascular disease
The two reviews identified for CVD [24,25] included 22 primary studies (six cohort, six case-control, ten 
cross-sectional) from nine countries. There were 3 108 248 participants, of which 3 060 517 (98%) were from 
one primary study [39].
Einarson et al [24] did not perform a meta-analysis, but reported that among people with diabetes in upper 
middle-income countries, the weighted average prevalence of stroke, myocardial infarction, and coronary ar-
tery disease was 6.9%, 3.4%, and 17.7%, respectively. In lower middle-income countries the weighted average 
prevalence of stroke and coronary artery disease was 6.3% and 27.3%, respectively, with no study reporting 
on the prevalence of myocardial infarction.
Based on our secondary meta-analysis of the eight studies (six case-control, two cross-sectional) from Poorzand 
et al [25], we found an overall OR for premature coronary artery disease of 2.35 (95% CI = 1.71-3.21) in peo-
ple with vs without diabetes in Iran, with low heterogeneity between studies (I2 = 25.5%, P = 0.225) (Figure 2).
Chronic kidney disease
We identified two reviews [26,27] on CKD occurrence amongst people with diabetes, one of which only in-
cluded two LMIC studies out of 71 included studies [26], while the other included 12 studies from Ethiopia 
[27]. The studies from the former were both cohort studies, including a combined total of 1114 participants 
with diabetes [26]. The annual cumulative incidence of CKD among people with diabetes in each primary 
study was 8.6% [40] and 8.1% [41].
We performed a secondary meta-analysis on the review by Shiferaw et al, which included two cohort, one 
case-control, and nine cross-sectional studies [27]. The authors provided prevalence estimates separately for 
CKD stages 1-5 and 3-5, so we did the same for our secondary meta-analysis. Seven cross-sectional studies 
were included for stages 1-5 and the pooled prevalence was 36% (95% CI = 26%-45%) (Figure 3, Panel A). 
For stages 3-5, 10 studies gave a pooled CKD prevalence of 15% (95% CI = 11%-19%) (Figure 3, Panel B). 
Heterogeneity for the two groups were both substantial, with I2>90%. Income level remained the same for 
Ethiopia throughout the study period, and all stage 1-5 studies were cross-sectional, which precluded sub-
group analyses. Subgroup analysis by study design for stage 3-5 studies was not performed due to having too 
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Table 3. Findings for each diabetes comorbidity from included systematic reviews and meta-analyses









Coronary artery disease: 17.7%
Lower middle-income countries:
Stroke: 6.3%
Coronary artery disease: 27.3%
Poorzand, 2019 [25]
Premature coronary artery disease OR = 2.35 (95% 
CI = 1.71-3.21)








Prevalence, stages 1-5: 36% (95% CI = 26%-45%)
I2>90%, P < 0.001 Study design for stages 3-5




Average prevalence: 36% N/A N/A
Uphoff, 2019 [29] Prevalence: 40% (95% CI = 34%-45%) I2 = 97.5%, P < 0.001 N/A
Hussain, 2018 [30] Prevalence: 38% (95% CI = 31%-45%) I2>90%, P < 0.001 N/A
Khalighi, 2019 [31] Prevalence: 61% (95% CI = 55%-67%) I2 = 98%, P < 0.001
Income level, depression 
assessment tool
Wang, 2019 [32]
Prevalence: 30.7% (95% CI = 16.6%-44.9%); OR = 3.05 
(95% CI = 1.11-8.37)
I2 = 99%, P < 0.001; 
I2 = 90.5%, P < 0.001
Study design, income level
Tuberculosis
Bailey & Ayles, 2017 
[33]
Adjusted OR range: 2.14 (95% CI = 1.32-3.46) to 19.3 
(95% CI = 6.1-61.0)
N/A N/A
McMurry, 2018 [34] Prevalence range: 0.1% to 4.9% N/A N/A
Al-Rifai, 2017 [35]
Risk estimate: 3.40 (95% CI = 1.53-7.56) I2 = 87.4%, P < 0.001
N/A
OR = 3.04 (95% CI = 2.29-4.03) I2 = 23.5%, P = 0.250
Lee, 2017 [36] OR = 1.16 (95% CI = 0.97-1.37) I2 = 0%, P = 0.608 N/A
Tegegne, 2018 [37] OR = 1.78 (95% CI = 1.26-2.52) I2 = 71.1%, P < 0.001
Study design, income level, 
confounder adjustment
*Prevalence estimates refer to the prevalence of each comorbidity among people with diabetes. Effect estimates refer to the risk or odds of the comorbidity in 
people with vs without diabetes.
†Subgroup analyses conducted as part of this umbrella review.
Depression
Four reviews on depression [28,30-32] included 528 987 par-
ticipants from 145 primary studies (142 cross-sectional and 
three case-control). An additional 41 cross-sectional studies, 
with an unknown number of participants, were from one re-
view which did not provide specific study characteristics [29]. 
A total of 16 LMICs were represented across all five reviews, 
with the majority being from India and Iran. Based on the 
five reviews, we found that in LMICs the average prevalence 
of depression, including major depressive disorder, in people 
with diabetes ranged from 30%-61%. We conducted second-
ary meta-analyses on three of these reviews [30-32].
The systematic review by Mendenhall et al focused specifically 
on LMICs and found that the average prevalence of depression 
in people with diabetes was 36% [28]. While Uphoff et al. [29] 
did conduct a meta-analysis, this was done rapidly so the au-
thors only provided aggregated study characteristics and a pooled depression prevalence. Due to this, we were 
not able to conduct our own secondary meta-analysis. Nonetheless, based on 43 estimates from 41 cross-sec-
tional studies from Bangladesh, India, and Pakistan, they found a pooled depression prevalence of 40% (95% 
CI = 34%-45%) in people with diabetes. They found substantial heterogeneity (I2 = 97%) and conducted me-
ta-regression analysis by publication year, country, disease (since they looked at various non-communicable 
Figure 2. 
Figure 2. Secondary meta-analysis of studies included in Poorzand 
et al. [25] showing the study-specific and summary estimates of the 
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diseases), sample size, diagnostic tool, and study quality. None 
of these variables fully explained the heterogeneity.
Hussain et al [30] included 43 cross-sectional studies from In-
dia and the pooled prevalence from our secondary meta-anal-
ysis was 38% (95% CI = 31%-45%). Heterogeneity was sub-
stantial (I2 = 99%, P < 0.001). Since India remained at the same 
income level when all the primary studies occurred, we could 
not do a subgroup analysis using income level.
Our secondary meta-analysis of Khalighi et al. [31] showed a 
much higher overall prevalence of depression in people with 
diabetes (61%, 95% CI = 55%-67%) compared to the oth-
er reviews, albeit with substantial heterogeneity (I2 = 98%, 
P < 0.001). This review only included studies from Iran, which 
was considered a lower-middle income country before 2009 
and an upper-middle income country from 2009 onwards 
[17]. Our subgroup analysis did not show any significant dif-
ference in the prevalence between the two income-level cate-
gorisations. Among the studies identified in this review, eight 
different depression assessment tools were used, with the Beck 
Depression Inventory (BDI) the most common, being used in 
75% of studies. In a post-hoc subgroup analysis comparing 
depression prevalence in studies using the BDI vs all other 
tools, the pooled prevalence was higher in the former than 
the latter studies (65%, 95% CI = 59%-71% and 48%, 95% 
CI = 33%-63%, respectively). Whilst between-subgroup het-
erogeneity was statistically significant (P = 0.028), there was 
still substantial heterogeneity within each subgroup (I2>97%, 
P < 0.001) (Figure 4).
In our secondary meta-analyses of LMIC studies included in 
the review by Wang et al [32 ], we computed both the pooled 
prevalence across all ten studies, and the pooled OR across 
the three case-control studies. The pooled prevalence of major 
depressive disorder in people with diabetes was 30.7% (95% 
CI = 16.6%-44.9%), with substantial heterogeneity between 
studies (I2 = 99%, P < 0.001) (Figure S1 in the Online Supple-
mentary Document). Subgroup analyses were not possible 
given too few studies in each subgroup. The pooled OR for the 
case-control studies was 3.05 (95% CI = 1.11-8.37), and also 
had substantial heterogeneity (I2 = 90.5%, P < 0.001) (Figure 
S2 in the Online Supplementary Document).
Tuberculosis
Of the five identified reviews on diabetes and TB [33-37], one 
focused on latent TB (LTB) [36] and one on multi-drug resis-
tant TB (MDR-TB) [37]. We performed narrative synthesis 
on two reviews [33,34] and secondary meta-analysis on three 
[35-37]. In total, these reviews included 300 659 participants 
from 22 LMICs amongst 47 primary studies (16 cohort, 15 
case-control, and 17 cross-sectional). One primary study from 
McMurry et al [34] reported on two separate cross-sectional 
studies from different countries, thus both were included in 
the study count. Generally, diabetes was shown to be associ-
ated with an increased risk of developing TB, although the as-
sociation for LTB was not statistically significant and only in-




Figure 4. Subgroup analysis from secondary meta-analysis of stud-
ies included in Khalighi et al. [31] showing the study-specific and 
summary estimates of the prevalence of depression in people with 
diabetes in Iran by depression assessment tool.
Figure 3. Secondary meta-analysis of studies included in Shiferaw et 
al. [27] showing the study-specific and summary estimates of the 
prevalence of chronic kidney disease among people with diabetes 
in Ethiopia for chronic kidney disease Panel A. Stages 1-5. Panel 
B. Stages 3-5.
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Bailey and Ayles [33] examined three primary studies on the 
association between diabetes and TB in African settings, but 
did not perform a meta-analysis due to between-study het-
erogeneity. The study specific adjusted ORs from these pri-
mary studies suggest that diabetes is associated with increased 
odds of TB, although effect estimates ranged from 2.14 (95% 
CI = 1.32-3.46) to 19.3 (95% CI = 6.1-61.0). McMurry et al 
included 17 primary studies and found that prevalence of TB 
amongst people with diabetes ranged from 0.1% to 4.9% [34].
Al-Rifai et al identified nine of their primary studies as be-
ing from LMICs, but based on the World Bank income clas-
sification used in our review, ten were eligible and thus in-
cluded in our secondary meta-analysis [35]. Since different 
effect measures were used across the primary studies, they 
could not all be combined. After pooling three primary stud-
ies which reported a hazard ratio, rate ratio, and relative risk, 
we found that diabetes was associated with a greater than 
3-fold increased risk of TB (summary estimate = 3.40, 95% 
CI = 1.53-7.56), with substantial heterogeneity between stud-
ies (I2 = 87.4%, P < 0.001; Figure 5, Panel A). Similarly, after 
pooling seven studies (five case-control, one cross-sectional, 
and one cohort) reporting odds ratios, we found that diabetes 
was associated with a 3-fold increased odds of TB (summary 
OR = 3.04, 95% CI = 2.29-4.03), with low heterogeneity be-
tween studies (I2 = 23.5%, P = 0.250; Figure 5, Panel B). There 
was no evidence of publication bias (Figure S3 in the Online 
Supplementary Document).
Lee et al [36] only included two cross-sectional studies on the association between diabetes and LTB in LMICs. 
The pooled summary suggested no significant association between diabetes and LTB (OR = 1.16, 95% CI = 0.97–
1.37; heterogeneity: I2 = 0.0%, P = 0.608; Figure S4 in the Online Supplementary Document).
Finally, Tegegne et al. [37] included 17 estimates from 15 studies (six cohort, six case-control, three cross-sec-
tional) from 10 LMICs across all WHO regions. Two studies [42,43] reported estimates separately for those 
with previously diagnosed TB and newly diagnosed TB. Our secondary meta-analysis of all 17 estimates found 
that people with vs without diabetes have 78% increased odds (OR = 1.78, 95% CI = 1.26-2.52) of developing 
MDR-TB, with moderate heterogeneity between studies (I2 = 71.1%, P < 0.001). Our study design subgroup 
analysis found a higher OR and low heterogeneity for case-control studies (OR = 2.13, 95% CI = 1.37-3.29; 
I2 = 26.6%, P = 0.235) compared to cross-sectional and cohort studies (Figure 6, Panel A). Our income-level 
subgroup analysis found similar OR estimates between lower and upper-middle income countries, with sub-
stantial and moderate heterogeneity, respectively (Figure 6, Panel B). We conducted a post-hoc analysis on 
confounder adjustment and found that the pooled estimate was higher for those studies that adjusted for at least 
one confounder, of which age, sex, smoking, and HIV status were the most common, compared to studies that 
did not adjust for any other factors (OR = 2.57, 95% CI = 1.92-3.43 vs OR = 1.16, 95% CI = 0.70-1.92; Figure 
6, Panel C). We also conducted a post-hoc analysis by WHO region to see if there may be regional differenc-
es. Heterogeneity remained moderate to substantial across regions, with the exception of the European region 
which showed no heterogeneity (I2 = 0.0%, P = 0.715). Only the estimates for South-East Asia and Europe were 
statistically significant; these regions also had the strongest association between diabetes and MDR-TB (Figure 
6, Panel D). There was no evidence of publication bias (Figure S5 in the Online Supplementary Document).
DISCUSSION
Our umbrella review identified 14 relevant systematic reviews on the association between diabetes and CVD, 
CKD, depression, and TB in 29 LMICs, nine of which included meta-analyses. However, no reviews on diabe-
tes and dengue or pneumonia were eligible for inclusion. Whilst there was some evidence for diabetes being 
associated with each of CVD, CKD, depression, and TB, the extent and quality of evidence varied across co-
morbidities. The evidence was most robust for the associations between diabetes and CVD and TB, for which 
there were a number of cohort studies. A lack of studies on the association between diabetes and CKD and 
Figure 5. 
Figure 5b. 
Figure 5. Secondary meta-analysis of studies included in Al-Rifai et 
al. [35] showing the study-specific and summary estimates of tu-
berculosis among people with diabetes. Panel A. Hazard, risk, and 
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the predominance of cross-sectional studies on the association between diabetes and depression reveal gaps in 
understanding of the association between diabetes and CKD and depression in LMICs, including among many 
countries for which no data were available.
Compared to findings previously reported from HICs, prevalence and effect estimates for depression and TB 
were generally higher in LMICs [44-46]. The higher estimates may reflect fewer resources and lower levels of 
funding for mental health care [47], a higher incidence of TB, and a high percentage of unmet need for diabetes 
care, in LMICs compared to HICs [48]. Our findings for CVD and CKD were comparable to HICs [7,26,49-
52], but this is based on very limited evidence. Further, although this umbrella review specifically searched 
for reviews from LMICs, only 59.9% of primary studies and 6.42% of the total number of study participants 
were actually from an LMIC.
Our review has a number of strengths. This is the first umbrella review to systematically synthesise the ex-
isting evidence on diabetes and the risk of multiple key comorbidities in LMICs. Our broad scope facilitated 
the investigation of the potential association between diabetes and both non-communicable and communica-
ble comorbidities, which is particularly relevant to LMIC settings which face a rising dual burden of commu-
nicable and non-communicable disease. Our use of secondary meta-analyses provided a new perspective on 
diabetes comorbidities by focusing specifically on the relationships in LMICs. The review also benefits from 
having used a detailed, comprehensive electronic search strategy and two reviewers to screen, select and ex-
tract data from articles.
Figure 6. Figure 6b. 
Figure 6c. Figure 6d. 
Figure 6. Subgroup analyses from secondary meta-analysis of studies included in Tegegne et al. [37] showing the study-specific and summa-
ry estimates of the odds of multi-drug resistant tuberculosis among people with diabetes. Panel A. Study design. Panel B. Country income 
level. Panel C. Confounder adjustment. Panel D. WHO region.
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This review has several limitations. First, it does not fully represent all the possible comorbidities with which 
diabetes could be associated. However, the diseases that were included are those commonly associated with 
diabetes both in LMICs and globally [7,12,53]. Second, given the lack of high-confidence reviews includ-
ed in this umbrella review, our conclusions are suitably cautious. Third, since primary studies were main-
ly cross-sectional, conclusions regarding the temporal sequence of diabetes and its comorbidities is limited 
[54]. However, omitting cross-sectional studies would have disproportionately restricted the scope of our 
review due to the dearth of longitudinal studies in LMICs. Fourth, secondary meta-analyses could be per-
formed for only nine reviews, and of those only two had sufficient studies to examine publication bias. Fi-
nally, meta-analyses found substantial between-study heterogeneity for the associations between diabetes 
and each of CKD, depression, and TB, the reasons for which are not clear. LMICs are a highly diverse group 
in terms of their culture, environment, and social determinants of health, and not accounting for these fac-
tors may explain the heterogeneity. We were only able to run a subgroup analysis on WHO region for one 
TB review [37], but it did not explain the observed heterogeneity, and there was insufficient information to 
explore additional subgroups.
We did not include any reviews on dengue or pneumonia, either due to eligible reviews being of critically low 
confidence in the case of dengue, or the lack of systematic reviews on the association between diabetes and 
pneumonia that included primary studies from LMICs. While dengue is more often studied in the context of 
LMICs compared to the other comorbidities we included, it is not often examined as an outcome of diabetes, 
which highlights a gap in our understanding of diabetes-dengue comorbidity. The majority of research has 
viewed diabetes as a risk factor for the progression to more severe forms of dengue, rather than as a risk fac-
tor for developing dengue. For example, a recent meta-analysis based on 12 studies (design and country not 
specified) found that among people who had less severe forms of dengue, diabetes was strongly associated 
with progression to severe dengue (OR 4.38, 95% CI = 2.58-7.43) [55]. With regard to pneumonia, a previ-
ous non-systematic literature review summarised evidence on diabetes and various pneumonias (including 
TB) globally, but the majority of evidence was for the association between diabetes and TB [56]. The authors 
acknowledged that there is limited evidence on the relationship between diabetes and pneumococcal, staph-
ylococcal, and influenza pneumonias, and that most of this comes from HICs [56].
Our general conclusion is that more research about diabetes comorbidities needs to be conducted in LMICs, 
especially for the comorbidities in which we found either no or few primary studies or reviews. Additionally, 
the bulk of the data identified in our review stems from studies conducted in Iran and India, so findings may 
not be representative of other settings. This highlights the need for more research in these underrepresented 
regions to gain a better understanding of the global impact of diabetes and its comorbidities. In particular, 
there should also be an emphasis on conducting larger, higher-quality, and cohort studies rather than sim-
ply increasing the quantity of small cross-sectional studies. However, for this to be done, there needs to be 
additional funding and resources available for research in LMICs. Once this high-quality primary evidence 
is available and synthesised in additional systematic reviews and meta-analyses, findings can be used to ap-
propriately inform policy.
Only then will it be possible to base LMIC policies and health priority setting on data that is representative 
of the LMIC context rather than the HIC context. Most of the disease management guidelines, treatments, 
and policy recommendations used in LMICs, especially with regard to non-communicable diseases, were ei-
ther developed in HICs or adapted from existing infectious disease programmes [57]. While LMICs can seek 
inspiration from strategies that have and have not worked in HICs, it is important that context-specific pro-
grammes grounded in relevant data are developed [58]. Additionally, LMICs may be able to learn from HIC 
experiences of developing and implementing integrated care models. While the structure of health systems, 
services, and funding varies across LMICs and differs from those in HICs, the horizontal approach that HICs 
have taken to integrate systems and services, for example for physical and mental health or for people with 
multiple conditions, may provide valuable examples for LMICs [59]. As this review has identified evidence 
for CVD, CKD, diabetes, and TB as comorbidities of diabetes, we recommend that these diseases are feasi-
ble targets for integrated care and increased screening and monitoring. However, specific recommendations 
will vary by country due to different disease distributions, health systems, and social structures. In countries 
with existing HIV programmes, another option could be to integrate additional health services into those 
programmes, especially as the population living longer with HIV has a higher risk of developing non-com-
municable diseases [60]. This is particularly relevant as the rising burden of non-communicable diseases, 
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CONCLUSION
This umbrella review identifies associations between diabetes and a number of key communicable and non-com-
municable diseases in LMICs. However, a lack of robust evidence, in particular the lack of cohort studies and 
limited number of participants in these settings, limits conclusions on the extent to which diabetes is associ-
ated with particular comorbidities in LMICs and whether associations differ to those in HICs. The shifting of 
the non-communicable disease burden to LMICs highlights the growing need to fill these gaps in understand-
ing to ensure that policies for primary and secondary prevention can be based on context-specific evidence.
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